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A B S T R A C T
Purpose: Aims of this studywere to estimate the ﬁrst-year medical care costs of newly diagnosed children
with structural-metabolic epilepsy and to determine the cost-driving factors in the selected population.
Method: This was a prevalence-based retrospective chart review that included patients who attended a
pediatric neurology clinic in a tertiary referral center in Malaysia. The total ﬁrst-year medical care costs
were estimated from the provider (i.e., hospital) perspective, using a bottom-up, microcosting analysis.
Medical chart/billing data (i.e., case reports) obtained from the hospital (i.e., provider) were collected to
determine the resources used. Prices or cost data were standardized for the year 2010 (One Malaysian
Ringgit MYR is equivalent to 0.26 Euro or 0.32 USD).
Results: Themost expensive item in the costs listwas antiepileptic drugs,whereas ultrasound examination
represented the cheapest item. Hospitalization and the use of non-antiepileptic drugswere the second and
third most costly items, respectively. The cost of therapeutic drug monitoring comprised only a small
proportion of the total annual expenditure. None of the demographic variables (i.e., gender, race, and age)
signiﬁcantly impacted the ﬁrst-yearmedical care costs. Similarly, child development, seizure type, therapy
type (i.e., polytherapy versus monotherapy), and therapeutic drug monitoring utilization were also not
associatedwith the cost ofmanagement. Theﬁrst-yearmedical care costspositively correlatedwith seizure
frequency (rs = 0.294, p = 0.001). However, the only variable that signiﬁcantly predict the ﬁrst-yearmedical
care costs was the type of antiepileptic drugs (R2 = 0.292, F = 7.772, p< 0.001).
Conclusion: This investigationwas the ﬁrst cost analysis study of epilepsy inMalaysia. The total ﬁrst-year
medical care costs for 120 patients with structural-metabolic epilepsy were MYR 202,816 (i.e., MYR
1690.13 per patient per year). The study ﬁndings highlight the importance of optimizing seizure control
in reducing the cost of management.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Pressure, in terms of the economic aspects of epilepsy, has been
increasing in both wealthier and poorer nations. In the richer
countries, an ongoing argument continues regarding how to
control the steady growth in health care expenditure. The inﬂation
of needs is a dilemma that it is pressuring the state-ﬁnanced health
care system. Therefore, emphasis is placed on ﬁnding the best
means to minimize the costs of health care. Alternatively, poorer
countries are experiencing a large need for health care but with
insufﬁcient resources. The irregular allotment of epilepsy care* Corresponding author. Tel.: +964 7713226872.
E-mail address: muhanad_rmk@yahoo.com (Muhannad R.M. Salih).
1059-1311/$ – see front matter  2012 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2012.08.005among countries, and sometimes within countries, does not
greatlymatch the actual requirements but, to a certain extent, does
match the underlying economic condition.1
In fact, about 80% of all health expenditure occurs in developed
countries, while the remaining 20% of economic resources is spent
in the rest of the world, where approximately 90% of the
individuals with epilepsy reside.2 Thus, it is imperative to think
about the economic aspects of the disease to improve the situation
of patients in all areas of the world.
It is essential to recognize that epilepsy is not a standardized
disorder, but rather the term describes several clinical situations
that exhibit the symptom of an epileptic seizure. When assessing
the requirement for care and the services available, it is common
that policy-makers (i.e., governments or insurance agents) do not
differentiate between the various types of epilepsy. Economically,vier Ltd. All rights reserved.
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epileptic patient, according to the frequency, severity, and type of
seizure. Oftentimes, epilepsy is associated with a primary disorder
that may persist even after remission of the seizures, such that not
all expenses or costsmay be attributable to epilepsy.1,3 Along these
lines, the International League Against Epilepsy (ILAE) replaced the
old terms idiopathic, symptomatic, and cryptogenic with modiﬁed
conceptual terms genetic, structural-metabolic, and unknown.4
The term refractory epilepsy may not be comparable among
different studies or settings, owing to the different assessment
criteria thatmay be adopted. However, more consistent ﬁgures can
be attained when patients are selected based on the new concept
(i.e., etiology). The term symptomatic, which was replaced by
structural-metabolic, is often substituted for the concept of a poor
prognosis or a challenging type of patients.4,5 Up to date, none of
the published cost studies were speciﬁcally focused on patients
diagnosed with structural-metabolic epilepsy.6–13
The focus of current investigation is to estimate the ﬁrst-year
medical care costs of newly diagnosed children with structural-
metabolic epilepsy and to determine the cost-driving factors in the
selected population.
2. Materials and methods
2.1. Setting
The study was conducted at the pediatric neurology clinic,
Hospital Pulau Pinang. This hospital is the main public hospital in
Penang Island. It is a tertiary referral center for the Northern
Territory, Peninsular Malaysia. At present, Hospital Pulau Pinang
has 3293 employees, with 115 specialists and 412medical ofﬁcers.
It has 1090 beds, covering a catchment area of approximately
750,000 people.14
2.2. Study design
A retrospective chart review was implemented. It was an
annual prevalence-based economic evaluation on patients
attended the Pediatric Neurology Clinic, Hospital Pulau Pinang.
The total ﬁrst-year medical care costs were estimated from the
provider (i.e., hospital) perspective, using a bottom-up, micro-
costing analysis. Medical chart/billing data obtained from the
hospital were collected to determine the resources used. Prices or
cost data were standardized for the year 2010 (One Malaysian
Ringgit MYR is equivalent to 0.26 Euro or 0.32 USD).
All patients who satisﬁed the following criteria were included:
(a) age 2 years; (b) newly diagnosed with structural-metabolic
(symptomatic) epilepsy based on clinical, electrophysiological, and
imaging investigations; (c) therapeutic management with antiep-
ileptic drugs (AEDs); (d) three or more visits during the ﬁrst year
from the referral time; and (e) received all of their medical care at
the Pediatric Neurology Clinic, Hospital Pulau Pinang. The
recruited children were followed for one year following the ﬁrst
visit.
The exclusion of patients <2 years of age was rationalized by
the considerable changes of physiological parameters during the
ﬁrst two years of life. Pediatric patients cannot be considered as
one homogeneous population. There are signiﬁcant differences in
physical, cognitive and psychosocial development. Infants and
toddlers (28 days to 23 months) have rapid mental, physical and
immune development. More to the point, drugs elimination may
exceed that in children >2 years of age. In that sense, there is a
huge variability in medication response, as the development does
not occur at the same rate in all pediatric patients.15
A comprehensive screening process of all medical records at the
Pediatric Neurology Clinic, Hospital Pulau Pinang was carried out.This screening targeted all patients who attended the clinic in the
past to the time of conducting the study. More than 1200 medical
records were screened, and only 255 ﬁles of them were belonged
for patients diagnosed with epilepsy. However, based on the
adopted inclusion criteria, only 132 patients were suitable to
be incorporated into this study. Medical records of the patients
were reviewed for information on patient’s demographic, clinical
characteristics, and resource utilization.
2.3. Manpower costs
To estimate the costs of each service or intervention utilized by
the recruited patients, an activity-based costing (ABC) approach
was employed. Accordingly, staff and/or head departments were
interviewed to determine the activities of each service or
intervention. Subsequently, a time-motion study was conducted
to estimate the costs of human resources. This was done by
measuring the time spent by staff to perform one single activity
several times using a stopwatch. Themonthly salary for each of the
involved employees was measured according to the pay scale of
the Federal Civil Services Ofﬁcers under the System of Remunera-
tion Malaysia.16 By assuming a daily working time of 8 h and a
monthly working time of 28 days, these monthly salaries were
converted into the cost or salary per minute (MYR/min). The mean
time (minute) spent by employees doing a speciﬁc activity was
multiplied by the salary per minute (MYR/min). Ultimately,
the total manpower cost incurred for a service or intervention
was the sum of human resource costs of all activities involved in
producing it.
2.4. Capital costs
The costs of furniture, and clinical and non-clinical machines
were obtained from the procurement section of each department.
However, some of these clinical machines were not purchased by
the hospital. Companies provided the machines to the hospital at
no cost (as reagent-rentals), but it is obligatory for the hospital to
buy consumables from the same providing companies. To keep
consistent with other Malaysian hospitals that do not adopt the
reagent-rentals approach and to enhance the generalizability of
the results, the costs of these reagent-rental machines were
acquired from the same providing companies, assuming that
Hospital Pulau Pinang bought these machines rather than reagent-
rented them.
The costs of the building were calculated by multiplying the
area of space in square feet by MYR 85, which represented the cost
of one square foot, according to the Hospital Pulau Pinang
Development Ofﬁce. Total capital costs were the sum of equivalent
annual costs of all assets involved in the intervention/service. Then,
the asset cost per sample/patient was the product of dividing total
capital costs by the total number of samples/patients exposed to
that particular intervention/service in the year 2009. Along these
lines, several assumptions were made. The useful life of a clinical
machine was assumed to be ﬁve years, whereas for furniture and
the building, the useful life was considered to be 10 and 30 years,
respectively.17Moreover, straight-line deprecationwith a discount
rate of 3% was assumed. At the end of the asset’s useful life, the
resale value was considered to be 10% of the initial costs.18
2.5. Consumable costs
Generally, data were collected as annual expenditure on
consumables for the year 2009, which was subsequently divided
by the total number of samples/patients receiving the service or
intervention. Many of these ﬁgures were gathered from the billing
data of the related department or by interviewing staff and/or head
Table 1
Health care resource utilization pattern.
Characteristic Utilization
n (% of patients) Mean SD
Outpatient clinic visits 563 (100) 4.691.47
Hospitalization 29 (17.5) 0.240.59
EEG 66 (54.2) 0.550.51
MRI 14 (11.7) 0.110.32
U/S 4 (3.3) 0.030.18
KUBa 3 (2.5) 0.020.15
Abdomen 1 (0.8) 0.0080.09
TDM 50 (26.7) 0.410.83
Laboratory tests 240 (35.8) 2.03.87
Biochemical 202 (30.8) 1.683.49
Hematological 33 (20) 0.270.72
Serological 5 (3) 0.040.30
a KUB: kidneys, ureters, and bladder.
Table 2
First-year medical care costs for the 120 patients.a
Cost element Cost (%)
Outpatient clinic visits 7974.33 (3.93)
Hospitalization 24,310 (12)
EEG 2876.47 (1.42)
MRI 5390.50 (2.66)
Ultrasound 87.22 (0.04)
TDM 2340.81 (1.15)
Laboratory testss 8015.12 (3.95)
AEDs 141,590.08 (69.81)
Non-AEDs 10,231.47 (5.04)
Total 202,816.00 (100)
a Cost is expressed in Malaysian Ringgit (MYR).
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able expenditure was already available for the majority of
laboratory tests conducted in the pathology department.
2.6. Medication costs
All drugs prescribed to the patients were included and
categorized as AEDs and non-AEDs. The drug unit costs were
based on the cost of acquisition of drugs by Hospital Pulau Pinang
and multiplied with the patient’s individual daily dose and
duration of therapy.
2.7. Hospitalization costs
The daily cost of hospitalization as a consequence of seizure
relapse or breakthrough seizure was based on the tariff by the
Planning and Development Division, Ministry of Health,
Malaysia.19 The costs of medications, laboratory tests, therapeutic
drug monitoring (TDM) tests, and diagnostic investigations were
not considered during the period of hospitalization as they were
already included in the tariff. The total cost of each admission was
the length of hospital stay (day) multiplied by MYR 286.
2.8. Estimation of the total intervention/service costs
Finally, the cost of each intervention/service was the sum of
total manpower costs, total capital costs, and total consumable
costs. However, the types of cost elements includedmay vary from
one intervention/service to another. The cost of pediatric
neurology clinic was completely based on manpower costs,
whereas the costs of electroencephalogram (EEG), radiological
investigation, laboratory tests, and TDM were based on the three
major elements (manpower, capital, and consumables).
2.9. Statistical analysis
Demographic and clinical characteristics of the patients were
analyzed by descriptive statistics. Normality of continuous
variables were tested by the nonparametric one-sample Kolmo-
gorov–Smirnov test (K–S test). All of the continuous variables were
non-normally distributed. Mean  SD and percentiles (25–50–75)
were calculated for the continuous variables. Percentages and
frequencies were used for the categorical variables. Comparison of
a continuous variable between two groups was done by Mann–
Whitney test. The Kruskal–Wallis test was applied to determine the
differences of continuous variables among 3 groups. The nonpara-
metric Spearman’s rho test was applied to test the correlation
between two continuous variables.
Lastly, the relationships between a continuous dependent
variable (ﬁrst-year medical care costs) and other independent
variables (patient’s seizure frequency, type of AEDs, therapy type,
child development, type of seizure, TDM utilization) were further
examined by multiple regression analysis. Variables were entered
into the regressionmodels simultaneously. All of the analyseswere
performed by using the PASW (Predictive Analytics SoftWare)
Statistics 18.0.
3. Results
3.1. Patients’ description
One hundred thirty two patients were recruited in this study
and 12 of themwere excluded because of missing/ambiguous data
and doubt associatedwith the etiology of epilepsy. Themean age of
the studied patients was 7.23  3.55 years with males slightly (59%)
higher than females (41%). With respect to racial distribution, threegroups of patientswere identiﬁed (Chinese, 42.5%;Malays, 32.5%; and
Indians, 25.0%). The proportions of patients with generalized (53%)
and focal (47%) seizures were almost comparable. During the follow-
up period, two-thirds of the patients received only old generation
AEDs (valproic acid, carbamazepine, clonazepam, phenobarbital, and
phenytoin) and only one-third of the patients received the newer
agents (lamotrigine, topiramate, vigabatrin, and gabapentin) as
adjuvant therapy. The baseline and last follow-up visit seizure
frequencywere 34.37  116.96 and 14.59  34.74 attacks per month,
respectively.
3.2. Resource utilization
For the 120 patients studied, a total of 563 outpatient clinic
visits were recorded. Twenty-nine in-patient admissions were
documented among the studied sample. The length of hospital stay
was 2.93  4.22 days. During the investigated period, 54% of the
patients received EEGs (only one patient had 2 EEGs). Fourteen
patientswere investigated bymagnetic resonance imaging (MRI), and
only 4 children received ultrasound (U/S). Thirty-two patients
received TDM services throughout the follow-up period. Fifty assays
were done for those TDM patients; eight were done during
admissions, and 42 tests were performed during outpatient clinic
visits. Approximately two-thirds of the patients did not have any
laboratory tests, whereas 240 tests were performed for the rest of the
children (Table 1).
3.3. Medical care costs
For the 120 patients studied, the cost of outpatient clinic visits
was MYR 7974.33, while the cost of hospitalization was MYR
24,310 (Table 2). The cost of EEG was MYR 2876.47, whereas the
cost of MRI was MYR 5390.50, and the cost of U/S was MYR 87.22.
Table 3
Variation of the ﬁrst-year medical care costs according different characteristics.a
Variables Patients, n Annual cost of epilepsy management p
Mean SD Percentiles (25–50–75)
Gender
Male 71 1653.951521.76 730.33–1181.49–2150.67 0.431b
Female 49 1742.561375.10 721.05–1428.08–1979.82
Race
Malay 39 1791.861436.59 750.63–1406.42–2332.44 0.646c
Chinese 51 1619.171441.05 755.00–1356.72–1832.88
Indian 30 1678.501555.56 544.98–1016.46–2660.31
Aged
<4 24 1763.431508.65 741.07–1302.85–1983.48 0.652c
4 to <8 47 1540.291069.18 755.00–1417.91–1832.88
8 to <12 32 1941.401878.05 796.14–1408.54–2467.33
12 17 1527.931482.57 429.23–807.39–2420.48
Development
GDD/IDe 61 1756.521322.08 929.24–1406.42–2150.78 0.144b
Normal 59 1621.491595.65 591.87–1050.63–1972.49
Seizure type
Focal 56 1704.641277.14 774.73–1423.00–2016.95 0.333b
Generalized 64 1677.431610.29 691.27–1151.95–2102.44
Therapy type
Monotherapy 39 916.40610.18 417.48–755.00–1417.91 <0.001b,h
Polytherapy 81 2062.671598.27 939.11–1458.81–2719.87
TDMf
Group A 32 2136.121727.97 1192.24–1531.23–2529.85 0.01b,h
Group B 88 1527.951321.14 593.45–1106.85–1968.80
Type of AEDsg
Group I 78 1183.23914.22 542.82–1038.67–1459.20 <0.001b,h
Group II 42 2631.511790.73 1337.98–2241.66–3699.88
a Cost is expressed in Malaysian Ringgit (MYR).
b Mann–Whitney test.
c Kruskal–Wallis test.
d Age categorization depended on the baseline assessment.
e GDD/ID: global developmental delay/intellectual disability.
f Group A; all patients who received TDM services at least once during the follow-up period. Group B; all patients who did not receive TDM services.
g Group I; all patients who only received old generation of AEDs. Group II; all patients who received new generation of AEDs as add on therapy.
h p<0.05 is considered statistically signiﬁcant.
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structural-metabolic epilepsy wasMYR 202,816 (i.e., MYR 1690.13
per patient per year).
3.4. Cost driving factors
Based on the univariate analysis, the ﬁrst-year medical care
costs showed no signiﬁcant difference between global develop-
mental delay/intellectual disability (GDD/ID) patients and nor-
mally developed patients (Table 3). Similarly, the variation in cost
was quite small between children with focal seizures and
others with generalized seizures. In contrast, the difference inTable 4
Multiple regression analysis on the ﬁrst-year medical care costs (patients n=120).
Variable Modalities
Seizure frequency (attack per year)
Type of AEDsa Group I, Gro
Therapy type Monotherap
Development GDD/IDb, no
Type of seizure Focal, genera
TDMc Group A, Gro
Model ﬁt
a Group I: all patients who only received old generation of AEDs. Group II: all patien
b GDD/ID: global developmental delay/intellectual disability.
c Group A: all patients who received TDM services at least once during the follow-u
 p<0.05 is considered statistically signiﬁcant.cost between patients utilizing monotherapy and polytherapy
was signiﬁcant (p < 0.001). Moreover, patients who received
TDM services had higher management costs than those who had
not received TDM services (p = 0.01). Likewise, children who
received the new generation AEDs as adjunctive therapy
generated higher costs than those who continued on old
generation AEDs alone (p < 0.001). None of the demographic
variables (i.e., gender, race, and age) showed any signiﬁcant effect
or impact on the ﬁrst-year medical care costs. Statistical analysis
demonstrated a signiﬁcant correlation between the patient’s
seizure frequency (attacks per year) and the ﬁrst-year medical
care costs (rs = 0.294, p = 0.001).Beta coefﬁcients (95% CI)
0.150 (0.410, 7.348)
up II 0.366 (548.733, 1683.635)
y, polytherapy 0.150 (110.225, 1045.523)
rmal 0.079 (704.989, 243.838)
lized 0.066 (692.036, 307.327)
up B 0.092 (854.054, 243.449)
R2 =0.292, F=7.772
ts who received new generation of AEDs as add on therapy.
p period. Group B: all patients who did not receive TDM services.
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tolerance values went above 0.1; likewise, the variance inﬂation
factor (VIF) values were also well below the threshold mark of 10.
Both of these ﬁgures signiﬁed that interpretation of the regression
coefﬁcients was not inﬂuenced by multi-collinearity. The model
ﬁt the data well (R2 = 0.292, F = 7.772, p < 0.001). The only
variable that signiﬁcantly inﬂuences the ﬁrst-year medical care
cost was the type of AEDs. In that way, the relation between
seizure frequency and type of AEDs was also examined. Patient’s
seizure frequency (attacks per year) was signiﬁcantly (p < 0.001)
higher in patients received new generation of AEDs as add on
therapy (42.82  95.63) than those who received only old genera-
tion of AEDs (13.35  31.62).
4. Discussion
In the present study, the cost of outpatient clinic visits
constituted only a small proportion (3.93%) of the total medical
care costs. This was totally compatible with the ﬁndings of a
prospective economic evaluation in Italy. The cost of medical
consultations in the ﬁrst year of management for newly diagnosed
children made up 3.68% of the total cost of management.8 In
contrast, a retrospective follow-up analysis in Hong Kong showed
that the cost of outpatient visits represented 39% of total
expenditures on epilepsy management.9 This can be rationalized
by the exclusion of the cost of laboratory tests, radiological
investigations (e.g., CT scan), and EEG in the above-cited study.
With respect to a developing country like India, the cost of
outpatient clinic visits accounted for 8.85% of the total expenditure
on epilepsy management.10 Unlike the current investigation,
questionnaires were used to gather the required data from
patients in the cited Indian study. Thus, patients with major
neurological disabilities were excluded from the study. In that
sense, this value may not be comparable with the present ﬁndings.
In this study, the cost of hospitalization accounted for 12% of
the total expenditure on epilepsy management. By searching the
literature, the proportion of admission costs showed a wide range
of variation among different studies.6–13,20 In Italy, a cost study on
newly diagnosed children with epilepsy demonstrated that
hospital admission and day hospital represented the main cost
of epilepsy during the ﬁrst year of management.8 Likewise,
hospitalization made up around 50% of the ﬁrst-year costs of
refractory epilepsy in newly diagnosed adults.20
This huge discrepancy can be attributed to the differences in the
selected population between these cited studies and the current
study. Further, a study from Oman showed that 52% of the cost of
epilepsy management was due to hospitalization.11 On the other
hand, statistics from other developing countries, such as India
(8.48%) and Burundi (22.3%), to some extent demonstrated
comparable ﬁndings to the current study.10,12
In the present study, the cost of diagnostic procedures (e.g., U/S,
MRI, and EEG) and laboratory tests made up only a small
proportion (8.07%) of the total medical care costs. Consistently,
the cost of investigative procedures and tests in newly diagnosed
epileptic children was only a small proportion of the ﬁrst-year
costs of management.8 In the United States, diagnostic procedures
and tests constituted about 12% of total cost of management in
newly diagnosed adults with epilepsy.20 Likewise, ﬁndings from a
retrospective multi-center study in India showed that only 7.3% of
the total cost of epilepsy management was related to investiga-
tions.10 Returning to the present study, only 1.15% of the total
expenditure on epilepsymanagement was spent on TDM. This was
consistent with results of a prospective observational study in
Oman, in which only 1% of the total expenditure on epilepsy
management was related to the assessment of plasma AED
levels.11 In Hong Kong, a retrospective cohort study showed thatapproximately 1.9% of total cost of epilepsy management was
attributed to TDM.9 Hence, the proportion of TDMcost in this study
was quite similar to that found in other studies.
In this study, AEDs were the most expensive cost element,
constituting approximately 70% of the total medical care costs.
Studies from developed countries, including the United Kingdom,
the United States, Italy, and Hong Kong, showed ﬁgures
contradictory to those from this study.6–9,20 In these cited studies,
the proportion of AED cost ranged from 10% to 34% of the total cost
of epilepsy management. Further, ﬁndings from a developing
country (Oman, 22.5%) were incompatible with that of the present
study.11 On the other hand, the cost of AEDs comprised 57.7% of the
total cost of epilepsy management in a retrospective study in
India.10
In one of the above-cited studies, the average daily dose was
used to estimate the cost of AEDs.7 Another study was based on
published literature and/or an expert panel of physicians.20 By
comparing these ﬁgures with that of the present study, the cost of
AEDs was individualized, and a micro-costing approach was
adopted. Moreover, most of the mentioned studies were not
conducted on pediatric populations. In addition, none of the stated
studies were exclusively based on patients newly diagnosed with
structural-metabolic epilepsy. These issues may explain the huge
discrepancies in the cost proportion of AEDs between this study
and the published literature.
In this study, the ﬁrst-year medical care costs were not
signiﬁcantly different among various demographic variables (i.e.,
gender, race, and age). Likewise, Child development, seizure type,
therapy type (i.e., polytherapy versus monotherapy), and TDM
utilization had no impact on the total medical care costs. However,
the cost was signiﬁcantly inﬂuenced by the use of new AEDs as
add-on therapy.
Consistent with the present ﬁndings, a retrospective study from
Burundi illustrated that cost was not associated with gender, age,
or seizure type.12 In a similar manner, a study from a developed
country (Germany) found that age, gender, and type of epilepsy
had no inﬂuence on the cost of epilepsy.13 In contrast, in Oman, a
prospective observational study revealed a signiﬁcant positive
association between age and cost.11 Further, higher cost was
observed for patients with generalized seizures than patients with
partial seizures. The ﬁndings of this cited study were obviously
inconsistent with that of the current investigation. The study
included patients aged 13 years, while the current study focused
on children aged2 years. Therefore, this conﬂict between the two
studies might be attributed to the disparity in the age of the
recruited patients.
The high cost associated with the use of new AEDs was
expected. This was supported by the ﬁndings of a previous study
conducted at the same clinic.21 The use of lamotrigine as one of the
new AEDs led to 103% increase in the medication costs. In the
present study, seizure frequency was found to be associated with
the ﬁrst-year medical care costs. This relationship between seizure
frequency and cost was reported earlier by several studies.7,13,22,23
In this investigation, patients who received new AEDs had higher
seizure frequency and cost than patients who only received the old
AEDs. In that sense, the type of AEDs used is the most inﬂuential
variable on the medical care costs.
In this study, selecting patients based on seizure diagnostic
scheme or underlying type of cause (etiology) may have some
novelty comparedwith previous studies. However, this study has a
number of limitations that must be addressed. The retrospective
evaluation of data taken from medical records has many
weaknesses which have restricted the adoption of the inci-
dence-based approach. Therewas a great deal of unclear ormissing
data,mostly for the epilepsy and seizure type. Hence, patientswere
excluded if they had poor documentation or missing data.
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investigation, the application of gross costing in estimating the
cost of hospitalization may undervalue the actual expenses of
several patients. For instance, children with status epilepticus may
require intensive care.
5. Conclusion
This investigationwas the ﬁrst cost analysis study of epilepsy in
Malaysia. The total ﬁrst-year medical care costs for 120 patients
with structural-metabolic epilepsy were MYR 202,816 (i.e., MYR
1690.13 per patient per year). The study ﬁndings highlight the
importance of optimizing seizure control in reducing the cost of
management.
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